A Comprehensive Literature Review
Prepared: 2026-10-05 Style: Vancouver numbered citations (all PMIDs mechanically verified via NCBI E-utilities esummary on the date of preparation) Seed source: Huang J, et al. Medicine (Baltimore). 2026;105(38):e50571. PMID 42760676 (double-blind RCT) Note: This review is prepared for personal knowledge; all factual claims carry citation numbers resolved in the reference list. Statistics are reproduced only where they could be verified against primary abstract/metadata records; figures that could not be verified are explicitly flagged or rejected.
Abstract
Postoperative pulmonary complications (PPCs) are the dominant source of morbidity after radical lung cancer surgery, affecting roughly one-quarter to one-third of patients undergoing lung resection and ranking first among causes of early postoperative death [1,2,3,4,5]. Their prevention has therefore become a central objective of thoracic enhanced-recovery and anesthesia practice. Esketamine — the S(+)-enantiomer of racemic ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist with roughly twice the analgesic and anesthetic potency of the racemate and a more favorable recovery profile [6,7,8,9] — has been proposed as a lung-protective, opioid-sparing agent on the strength of consistent preclinical anti-inflammatory data and a rapidly growing thoracic-surgery randomized controlled trial (RCT) literature [10,11,12,13,14]. The seed publication for this review, a 2026 double-blind RCT of 80 patients undergoing thoracoscopic radical lung cancer resection, reported that perioperative esketamine reduced the incidence of PPCs on postoperative day 1 from 72.5% to 37.5% (P = 0.002), but found no difference on postoperative days 3 or 7 and no difference in any secondary outcome [15]. This review situates that single-center finding within the full evidence chain: (1) the definitional heterogeneity and true burden of PPCs; (2) the pharmacology and enantiomer-specific properties of esketamine; (3) the preclinical mechanisms linking NMDA antagonism to attenuated lung injury (NMDAR2A–NF-κB/NLRP3–GSDMD pyroptosis, caspase-11–GSDMD signaling, TLR4–NF-κB–NLRP3, TGF-β–Smad3 macrophage repolarization, and gut–lung-axis immunomodulation) [16,17,18,19,20,21]; (4) the clinical thoracic RCT evidence base, in which the largest and most recent trials show consistent improvements in oxygenation, pulmonary mechanics, quality of recovery, pain, mood and sleep but inconsistent effects on hard PPC endpoints [12,13,22,23,24,25,26,27,28]; (5) adjacent evidence in bariatric and general surgery suggesting a PPC reduction that may be mediated chiefly by avoidance of opioid-induced respiratory depression and hypoxemia [10,29]; and (6) the sobering record of non-pharmacologic and ventilatory PPC-prevention trials, including two large phase 3 null trials (PROTHOR and PRIME-AIR) and the high-certainty, low-FiO₂ and protective-ventilation signals, which frame how much a single drug can plausibly contribute [30,31,32,33,34,35]. Pooled and mechanistic data support esketamine as a rational opioid-sparing adjunct in thoracic anesthesia with probable benefit on secondary respiratory and recovery outcomes, while the specific claim that it reduces clinically meaningful PPCs rests on small, single-center trials with heterogeneous definitions, short follow-up, and early-transient endpoints. The one consistent safety signal worth surveillance is a retrospective excess of postoperative atrial fibrillation/flutter with perioperative ketamine exposure [36]; psychotomimetic and dissociative effects are dose-related and generally mild at subanesthetic doses [37,38]. The review concludes with an explicit limitations section, a proposed minimum reporting standard for future PPC trials of esketamine, and the trial-registry landscape.
1. Introduction and Historical Context
Lung cancer remains among the leading causes of cancer death worldwide [107], and surgical resection — increasingly by video-assisted thoracoscopic surgery (VATS) — offers the best chance of cure for early-stage disease in eligible patients [5]. The operation itself, however, is intrinsically hostile to the lung: one-lung ventilation (OLV), surgical collapse and manipulation of the operative lung, lymph-node dissection, chest-drain placement, and postoperative pain that splints coughing and deep breathing together create a high-risk respiratory milieu [1,2,3,4]. PPCs — broadly encompassing atelectasis, pneumonia, respiratory failure, bronchospasm, pleural effusion, pneumothorax, and aspiration pneumonitis — are consequently the most frequent serious events after thoracic surgery, prolong hospitalization, increase intensive-care utilization, degrade quality of life, and independently predict mortality [1,2,5,40,41].
Anesthesia has long been implicated in this risk. Opioids, the historical backbone of intraoperative and postoperative analgesia, produce dose-dependent central respiratory depression, reduce cough and mucociliary clearance, and can contribute to postoperative hypoxemia and hypercapnia — the very pathophysiological substrate of early PPCs [42,43]. The opioid-sparing and opioid-free anesthesia (OFA) movements, catalyzed by the opioid crisis and by enhanced-recovery principles, therefore offered a testable hypothesis: if opioids are replaced with multimodal non-opioid analgesics, respiratory complications should fall [44,45,46,47]. Esketamine has emerged as a leading candidate for that role in thoracic anesthesia because it combines potent analgesia with preserved spontaneous ventilation, bronchodilation, minimal respiratory depression, and — uniquely among NMDA antagonists — a reputed anti-inflammatory, lung-protective profile [6,7,8,9,16,17,18,19,20,21].
The mechanistic case for esketamine in the lung is comparatively young. Racemic ketamine was introduced into clinical anesthesia in 1970 and is familiar chiefly as a dissociative anesthetic and analgesic [9,48]. Its S(+)-enantiomer, esketamine, was developed for its greater NMDA-receptor affinity and potency and was later repurposed and licensed (2019) as intranasal esketamine for treatment-resistant depression, bringing it into a renewed regulatory and clinical spotlight [8,9,48,49,50]. In parallel, a large Chinese thoracic-anesthesia literature — reflecting the sheer volume of lung cancer surgery in China — has accumulated dozens of small RCTs of perioperative esketamine in thoracoscopic lung resection, with endpoints spanning oxygenation, inflammatory cytokines, quality of recovery, postoperative sleep, mood, cognition, and PPCs [12,13,22,23,24,25,26,27,28,51,52,53]. The seed trial belongs to this literature, and its central result (a halving of early PPCs with no downstream difference) is the kind of signal that demands careful, critical synthesis rather than uncritical adoption.
This review addresses seven questions: (1) How are PPCs defined, and how common are they after radical lung cancer surgery? (2) What are the pharmacology and enantiomer-specific properties of esketamine? (3) What preclinical mechanisms plausibly link esketamine to lung protection? (4) What does the clinical trial evidence show for PPCs and for related thoracic outcomes? (5) What does the adjacent non-thoracic evidence contribute? (6) How does esketamine compare with, and fit within, the broader PPC-prevention evidence hierarchy? and (7) What are the limitations, open questions, and defensible clinical conclusions?
2. Postoperative Pulmonary Complications: Definitions, Burden, and Risk
2.1 Definitional heterogeneity is the first obstacle to interpretation
There is no universally accepted definition of a PPC, and this heterogeneity is not a scholarly footnote — it directly determines the apparent effect size of any preventive intervention [3,33]. The most influential frameworks are: (i) the European Perioperative Clinical Outcome (EPCO) definitions developed by the ESA–ESICM joint taskforce, which define 22 individual adverse events with severity grading and four composite outcome measures [54]; (ii) the StEP-COMPAC (Standardised Endpoints for Perioperative Medicine–Core Outcome Measures for Perioperative and Anaesthetic Care) group’s consensus definitions [55]; (iii) the ARISCAT composite of respiratory infection, respiratory failure, bronchospasm, atelectasis, pleural effusion, pneumothorax, or aspiration pneumonitis [56]; and (iv) the Melbourne Group Scale (MGS), a physiologically anchored, treatment-relevant scoring tool validated for thoracotomy and lung resection [57]. The seed trial and most Chinese thoracic RCTs do not specify which framework they used, which limits cross-trial comparability [15].
The practical consequence is large. In one prospective thoracotomy cohort, the same 129 patients yielded PPC incidences of 6% (Gosselink score), 13% (MGS), and 40% (Brooks-Brunn score) depending on the tool used, against a clinically observed treated-PPC rate of 12% [57]. Contemporary trials compound the problem by using composite endpoints of differing granularity: PRIME-AIR used a graded 0–4 composite across ten PPC types [35]; PROTHOR used a 13-item composite [31]; the JAMA low-tidal-volume trial used an eight-item composite [34]; and the seed trial used an unspecified PPC definition [15]. A drug can therefore appear to “work” or “fail” largely as a function of instrument choice and follow-up window. This is the single most important methodological caveat for the entire field.
Table 1. Selected PPC definitions and their implications.
| Framework / trial | Components | Composite or graded | Population | Reported incidence |
|---|---|---|---|---|
| EPCO / ESA–ESICM [54] | 22 adverse events with severity grading; 4 composites | Graded | Broad perioperative | Definitional standard |
| StEP-COMPAC [55] | Consensus core outcome set | Graded | Perioperative research | Definitional standard |
| ARISCAT (Canet 2010) [56] | Respiratory infection, respiratory failure, bronchospasm, atelectasis, pleural effusion, pneumothorax, aspiration pneumonitis | Composite | Population-based, 59 hospitals | 5% (123/2,464) |
| Melbourne Group Scale [57] | Physiologic + treatment-based items | Score | Thoracotomy/lung resection | 13% (MGS) |
| PRIME-AIR [35] | Hypoxemia, respiratory symptoms, atelectasis, bronchospasm, infection, hypercapnia, pneumonia, effusion, pneumothorax, ventilatory dependence | Graded 0–4 | Open abdominal, ARISCAT ≥26 | ~56% grade 2 |
| PROTHOR [31] | 13 respiratory events incl. ARDS, prolonged air leak | Composite | Thoracic OLV | 53.6% vs 56.4% |
| JAMA low-tidal-volume [34] | Pneumonia, bronchospasm, atelectasis, congestion, respiratory failure, effusion, pneumothorax, unplanned ventilation | Composite | Major non-cardiac surgery | 38% vs 39% |
2.2 Incidence after lung resection and in high-risk surgical populations
Across the surgical spectrum, PPCs complicate roughly 5% of unselected procedures but rise steeply with intrathoracic and upper-abdominal surgery, age, and comorbidity [56,58,59]. In the prospective ARISCAT validation cohort (5,099 patients, 63 European centers), PPCs occurred in 7.9%, with predicted-versus-observed rates of 0.87% versus 3.39% in low-risk, 7.82% versus 12.98% in intermediate-risk, and 38.13% versus 38.01% in high-risk patients — demonstrating that ARISCAT calibrates well at the extremes [58].
After lung resection the numbers are substantially higher. A retrospective Brazilian series of 196 pulmonary resections reported PPCs in 20%, with ASA ≥3, lower corrected diffusing capacity, and increasing age as independent risk factors [60]. In elderly patients (≥70 years) undergoing VATS lobectomy, PPCs occurred in 35.7% (115/322), with ASA ≥III, longer OLV duration, smoking, and COPD as independent predictors [40]. A German multicenter registry of thoracotomy for non-lung-cancer indications (n = 1,368) found PPCs in 278 patients and association with markedly increased in-hospital mortality (7.2% vs 1.5%) [5]. After thoracoscopic anatomical resection (n = 1,192), the PPC rate was 26.7%, with pneumonia most common (16.0%), and preoperative hypoalbuminemia an independent risk factor [61]. In stage I NSCLC patients undergoing VATS, PPCs occurred in 27.6% and independently predicted persistent cough, dyspnea, and delayed recovery up to 90 days [41]. Contemporary narrative and systematic reviews converge on a figure of roughly 20–35% after thoracic oncologic resection and up to 30–50% in the highest-risk subsets [1,4,5,62]. This is an order of magnitude higher than the general-surgical baseline and explains why thoracic surgery is the preferred arena for PPC-prevention trials.
2.3 Risk prediction: ARISCAT and its successors
The ARISCAT score — derived by Canet et al. from 2,464 patients in 59 Spanish hospitals (2010) — remains the most widely validated generic PPC prediction tool [56]. Its seven independent predictors are low preoperative arterial oxygen saturation, acute respiratory infection in the prior month, age, preoperative anemia, upper-abdominal or intrathoracic surgery, surgery lasting ≥2 hours, and emergency surgery; discrimination was excellent (AUC 0.90 development, 0.88 validation) [56]. External validation in 5,099 patients confirmed good discrimination (c-statistic 0.80) and calibration [58]. It has since been validated in major emergency abdominal surgery (AUC 0.83; predicted 24.9% vs observed 36.1%) [63], while other single-center validations have been disappointing (laparotomy AUC 0.567) [41] and comparative testing in critically ill surgical patients found all of LAS VEGAS, ARISCAT, and CHI-BPRI to have suboptimal discrimination (AUCs 0.55–0.63) [64]. A 2025 systematic review and meta-analysis of 116 prediction models (123 studies; 14 models meta-analysed) found ARISCAT to have summary c-statistic 0.76 (95% CI 0.67–0.86) for composite PPCs, with Xue’s model (0.82) and CARDOT (0.73) comparable or better and disease-specific models reaching 0.85–0.90 for pneumonia and respiratory failure [65].
For thoracic surgery specifically, generic tools underperform, motivating thoracic-specific models. A prospective nomogram for older patients (≥65 years) undergoing non-cardiac thoracic surgery incorporated eight predictors (age, surgical approach, desaturation <92% for >2 minutes, surgery duration, smoking, FEV₁/FVC%, respiratory infection within 30 days, and neoadjuvant chemotherapy) and achieved AUC 0.866 (development) and 0.825 (external validation) [66]. Preoperative inflammatory indices add incremental signal: elevated systemic immune-inflammation index and neutrophil-to-lymphocyte ratio were independently associated with PPCs in stage I–II NSCLC (highest-quartile adjusted ORs 5.53 and 5.88, respectively), though discrimination was modest (SII AUC 0.686) [67].
A recurring, practice-relevant theme is that many determinants of PPC risk are not modifiable (age, anatomy, prior thoracic surgery), which shifts emphasis to modifiable procedural and anesthetic factors: duration of OLV, smoking, fluid strategy, neuromuscular blockade and reversal, ventilation strategy, oxygenation targets, and analgesic regimen [2,4,5,40,68]. Esketamine belongs to the last of these domains, and its trial literature is best read as an attempt to modify the analgesic-ventilatory axis rather than to alter a patient’s intrinsic risk.
3. Esketamine: Pharmacology and Mechanism
3.1 Chemistry, enantiomers, and pharmacokinetics
Racemic ketamine is a 1:1 mixture of two enantiomers; the dextrorotatory S(+)-enantiomer (esketamine) has approximately four times the affinity for the NMDA receptor of the levorotatory R(−)-enantiomer (arketamine) and is roughly twice as potent as an analgesic and anesthetic [8]. This potency difference permits an approximately 50% dose reduction relative to racemic ketamine for equivalent anesthesia/analgesia, accompanied by higher clearance and shorter recovery time [8]. A landmark 2024 narrative review of the anesthesia literature (1980–2022) concluded that esketamine and racemic ketamine are not equivalent at clinically equivalent analgesic/anesthetic doses: psychomimetic effects relate essentially to NMDA blockade and esketamine is not free of unwanted mental effects, but cognitive disturbance during arousal and recovery is less frequent and pronounced with esketamine, and esketamine shows cardiocirculatory-stabilizing and neuroprotective properties against placebo [8]. Analgesic efficacy evidence is described as inconsistent, motivating direct head-to-head equi-analgesic comparisons with the racemate [8].
Esketamine is hepatically metabolized (principally by CYP3A4 to norketamine and downstream metabolites), is available as intravenous racemic-free product and as intranasal spray, and has an elimination context that favors short procedures and day-surgery protocols [8,49]. In the perioperative setting it is most commonly given as a subanesthetic bolus (0.2–0.5 mg/kg) followed by an infusion (0.125–0.25 mg/kg/h) or incorporated into patient-controlled intravenous analgesia (PCIA) at 0.015–0.03 mg/kg/h [22,23,24,25,26,27,28]. The 2019 FDA/EMA approval of intranasal esketamine for treatment-resistant depression accelerated clinical trial activity across both psychiatric and non-psychiatric indications: a 2025 quantitative analysis of 363 trials (2014–2024) found anesthesia (~22%) and pain management (~28%) dominant for ketamine and treatment-resistant depression (~29%) for esketamine, with subanesthetic dosing representing a growing novel-therapeutic avenue [49]. Approved and emerging indications continue to expand, including perioperative analgesia, sleep disturbance, postpartum depression, and procedural sedation [49].
3.2 NMDA antagonism, analgesia, and the opioid-sparing rationale
Esketamine’s clinical value in thoracic anesthesia rests on a favorable combination: non-opioid analgesia, preservation of respiratory drive and airway reflexes, bronchodilation, and hemodynamic stability [6,7,8]. Meta-analytic evidence supports modest but consistent acute postoperative pain reduction and opioid sparing. A 2021 systematic review of 12 RCTs (905 patients) found perioperative intravenous S-ketamine improved resting pain scores at 4, 12, and 24 hours (SMD −1.11, −0.88, and −0.39, respectively) but not at 48 hours and not for movement pain, with moderate GRADE certainty [69]. A larger 2026 meta-analysis of 35 RCTs (3,831 patients) restricted to intraoperative low-dose esketamine (<1 mg/kg) found significant resting-pain reduction at 4, 12, 24, and 48 hours and movement-pain reduction at 12, 24, and 48 hours, reduced rescue analgesia (RR 0.52), reduced morphine consumption at several time points, and modest propofol sparing, with no significant increase in nausea, agitation, dizziness, or hallucinations [37]. A 2024 meta-analysis of 18 RCTs (1,554 patients) found ketamine/esketamine improved subjective quality of recovery on postoperative days 1 and 2 and reduced anxiety and depression scores without increased adverse events or length of stay, though the subgroup effect was driven by esketamine and by Chinese trials [70]. Within obesity, a network meta-analysis of 37 RCTs (3,602 patients) found that multiple non-opioid adjuvants reduced opioid consumption and that ketamine/esketamine specifically reduced postoperative pulmonary complications [10] — an important non-thoracic signal discussed in Section 5.
3.3 Preclinical mechanisms of lung protection
The mechanistic case for esketamine as a lung-protective agent has strengthened materially since 2024, and it is unusually coherent for an anesthetic drug. Five intersecting pathways recur (Table 3).
NMDAR2A–NF-κB/NLRP3–Caspase-1–GSDMD pyroptosis. In LPS-induced septic acute lung injury (ALI), esketamine reduced histopathological injury, pulmonary edema (wet/dry ratio), inflammatory cytokines, and neutrophil extracellular trap formation; NMDAR2A immunoreactivity co-localized with lung macrophages; and in RAW264.7 macrophages esketamine inhibited NF-κB/NLRP3/Caspase-1/GSDMD signaling and attenuated pyroptosis. MK-801 (NMDA antagonist) mimicked and NMDA agonist reversed the effect, establishing receptor dependence [16].
Caspase-11–GSDMD atypical pyroptosis and PI3K/AKT. In cecal-ligation-and-puncture ALI, esketamine improved lung architecture, reduced edema and inflammation, inhibited caspase-11 and GSDMD-N expression, lowered IL-1β, and reversed PI3K/AKT inhibition [17].
TLR4–NF-κB–NLRP3 oxidative stress. In limb ischemia-reperfusion ALI, esketamine reduced edema, inflammatory infiltration, and oxidative stress (restored SOD, reduced MDA), suppressed the TLR4/NF-κB/NLRP3 axis, and lowered BALF/serum cytokines; TLR4 activation with LPS reversed these benefits [18].
TGF-β–Smad3 macrophage repolarization. In E. coli sepsis, esketamine suppressed LPS-induced M1 markers (TNF-α, IL-1β, IL-6, iNOS) and enhanced M2 markers (Arg-1, CD206, IL-10, Fizz1), attenuated lung injury, reduced serum ALT/AST/lactate, and lowered TNF-α/IL-6 in serum and BALF; the Smad3 inhibitor SIS3 abolished both M2 polarization and organ protection [19].
Gut–lung and gut–brain–lung axis. Ketamine and its enantiomers modulate systemic immunity and organ protection partly through the gut microbiota, microbial metabolites, and intestinal immune-cell trafficking, limiting bacterial translocation and mesenteric lymph inflammatory signaling, and reducing pulmonary infiltration of pro-inflammatory cells [20]. In a COPD-depression comorbidity rat model, esketamine improved pulmonary function and behavior, reduced neuronal apoptosis and microglial activation, suppressed MAPK/NF-κB signaling, and partially restored gut and lung microbiota balance [21].
Two additional cancer-biology findings are relevant to lung cancer surgery specifically and warrant cautious interpretation. Esketamine reduced proliferation, migration, and invasion in esophageal squamous carcinoma cells in vitro [39], and reduced lipopolysaccharide-induced septic lung injury [16]; and in postoperative lung cancer patients, early esketamine exposure altered the tumor metastatic microenvironment [71]. Conversely, the glutamate NMDA receptor subunit GRIN2D (encoded by GRIN2D) was found to promote lung cancer growth, raising the theoretical question of whether NMDA blockade could influence tumor biology [72]. These are hypothesis-generating, preclinical/surrogate findings; none is an established clinical benefit or harm, and they should not drive perioperative decision-making.
Table 3. Preclinical mechanisms of esketamine-associated lung protection.
| Pathway / model | Key findings | Source |
|---|---|---|
| LPS ALI; NMDAR2A on macrophages | ↓injury, edema, cytokines, NETs; ↓NF-κB/NLRP3/Caspase-1/GSDMD; MK-801 mimics, NMDA reverses | [16] |
| CLP endotoxin ALI | ↓injury, edema, IL-1β; ↓caspase-11/GSDMD-N; PI3K/AKT involvement | [17] |
| Limb ischemia-reperfusion ALI | ↓oxidative stress (↑SOD, ↓MDA); ↓TLR4/NF-κB/NLRP3; LPS reverses | [18] |
| E. coli sepsis | M1→M2 repolarization; ↓lung injury and ALT/AST; Smad3-dependent | [19] |
| Gut–lung/gut–brain–lung | Microbiota and immune-cell trafficking modulation; ↓bacterial translocation | [20] |
| COPD-depression rat | ↑pulmonary function, ↓MAPK/NF-κB, partial microbiota restoration | [21] |
| Esophageal cancer cells / lung cancer | Antiproliferative effects in vitro; GRIN2D promotes lung cancer growth | [39,71,72] |
3.4 The opioid-free anesthesia hypothesis
The mechanistic bridge from esketamine’s analgesic profile to reduced PPCs is the avoidance of opioid-related respiratory depression. A randomized trial of esketamine-based OFA with quadratus lumborum block in lower abdominal/pelvic surgery found lower IL-6, IL-8, TNF-α, and CRP in the esketamine group, supporting an anti-inflammatory effect of opioid elimination [42]. In thoracoscopic lung resection, OFA reduced postoperative nausea and vomiting relative to opioid-based anesthesia in an RCT [45] and was feasible in retrospective propensity-matched VATS cohorts [46]; esketamine-based OFA also facilitated spontaneous-ventilation VATS [47]. The plausible causal chain — less opioid → less respiratory depression and sedation → better cough, mobilization, and alveolar recruitment → fewer early atelectasis/hypoxemia events — is testable and is supported indirectly by the early (postoperative day 1) and hypoxemia-specific nature of the positive PPC signals [10,15].
4. Clinical Evidence: Esketamine and PPCs After Radical Lung Cancer Surgery
4.1 The seed randomized trial
The seed publication is a single-center, randomized, double-blind controlled trial of 80 adults undergoing thoracoscopic radical resection for lung cancer [15]. Patients received perioperative esketamine or control; the primary outcome was the overall incidence of PPCs on postoperative day 1. The incidence was 37.5% in the esketamine group versus 72.5% in the control group (P = 0.002). There were no significant between-group differences in PPC incidence on postoperative days 3 or 7, nor in PPC severity score, postoperative nausea and vomiting, postoperative hospital stay, thoracic drainage-tube indwelling time, 24-hour resting visual analog pain score, unplanned ICU admission, or postoperative mortality [15]. The authors concluded that perioperative esketamine reduces early (day 1) PPC incidence without affecting other clinical outcomes [15].
Three features of this result deserve emphasis. First, the control-group day-1 PPC rate (72.5%) is far above the incidence reported in most thoracic cohorts (20–35%) [40,41,60,61], suggesting either a broad/unspecified PPC definition, a high-risk enrolled population, or detection of transient, self-limited events — a pattern that inflates absolute risk differences. Second, the treatment effect is confined to the earliest measurement and disappears by day 3, which is most consistent with attenuation of early opioid-related hypoxemia/atelectasis rather than prevention of established pneumonia or respiratory failure. Third, the trial is small (n = 80) and single-center, and its results have not yet been independently replicated at scale [15].
4.2 Thoracic and lung-cancer RCT evidence
The broader thoracic RCT literature (Table 2) is consistent in showing improvements in physiologic and patient-centered surrogates but heterogeneous on PPC incidence:
- Lung-protective / oxygenation outcomes. A three-arm RCT in VATS (n = 145) compared low-dose and high-dose esketamine with control and found that control patients had lower arterial-alveolar oxygen partial-pressure ratio (a/A) and oxygenation index, higher respiratory index and alveolar-arterial oxygen difference at ICU discharge and 24 hours, a higher incidence of PPCs, and higher pain scores at 24–48 hours; esketamine attenuated hemodynamic fluctuation, but the optimal dose-effect relationship was not established [12]. In elderly patients undergoing thoracoscopic lung cancer surgery (n = 160), esketamine combined with distal limb ischemic preconditioning lowered CC-16, SP-D, and TNF-α, shortened hospital stay, and reduced lung infection and atelectasis relative to control, with the combination superior to either alone [22]. An earlier RCT (n = 80) found postoperative esketamine infusion added to sufentanil reduced low minute ventilation (P = 0.014), PPCs (P = 0.039), and hypoxemia (P = 0.003), and improved second-day pain and sleep [13].
- Combination with dexmedetomidine. In mild-to-moderate COPD patients undergoing VATS (n = 60, four groups), pre-induction esketamine and esketamine–dexmedetomidine both lowered peak and plateau airway pressures, raised dynamic compliance, reduced IL-6/IL-8 and MDA, and raised IL-10 and SOD at 2 hours of OLV; the combination improved PaO₂ more than either alone [11]. A published comment on this trial is indexed separately [73].
- Non-inferiority against an active comparator. A double-blind non-inferiority RCT (n = 126; 120 analysed) in thoracoscopic surgery found esketamine non-inferior to dexmedetomidine for the PaO₂/FiO₂ ratio 60 minutes into OLV (adjusted mean difference −1.92 mmHg; 95% CI −41.06 to 37.20) and associated with better intraoperative respiratory mechanics, lower opioid requirement, and higher quality-of-recovery scores — but no difference in PPC incidence (P = 0.86) [23]. This is a particularly informative trial because it demonstrates that a favorable oxygenation surrogate does not automatically translate into fewer clinical PPCs.
- Quality of recovery. An RCT in elderly patients (≥60 years, n = 144) undergoing thoracoscopic radical lung cancer resection found esketamine-based multimodal low-opioid anesthesia improved QoR-15 on postoperative day 3 (121 vs 115; P < 0.001), chiefly in physiologic comfort, emotional state, and pain [24]. In thoracoscopic lung resection, subanesthetic esketamine improved QoR-15 at 24 hours (difference 6.1; 95% CI 4.0–8.1; P < 0.001) in a 2×2 factorial trial against erector spinae plane block (ESPB) versus intercostal nerve block (ICNB) [25]. Perioperative S-ketamine also improved QoR-40 at 48 hours after VATS (median 181.5 vs 174.5; P < 0.001) and reduced opioid rescue [26].
- Neurocognitive and mood endpoints. A single intraoperative 0.5 mg/kg esketamine dose in non-cardiac thoracic surgery reduced anxiety and depression scores on postoperative days 1 and 3 and lowered S100β and IL-6 while raising BDNF, without behavioral cognitive improvement [51]. Perioperative esketamine reduced depressive symptoms at one month after thoracoscopic lung cancer surgery (1.3% vs 11.8%; risk difference −10.5%; P = 0.018) [52]; a similar trial in frail elderly patients found lower HAMD-17 scores, better sleep, and favorable BDNF/5-HT/S100β/NSE changes [53]. Esketamine-based OFA in elderly thoracoscopic surgery did not significantly reduce postoperative cognitive dysfunction (20% vs 42.5%, P = 0.054) but improved reaction time and hemodynamic stability [27], and intraoperative esketamine lowered POCD incidence after pulmonary lobectomy in a single-blind trial [74]. A single subanesthetic intraoperative dose reduced moderate-to-severe pain and sleep disturbance in elderly thoracoscopic lung surgery (NNT 5.7) [75].
- Pain and regional-anesthesia combinations. Adding esketamine to paravertebral or intercostal blocks consistently reduced opioid consumption and pain (e.g., 48-hour sufentanil consumption 30.2% lower with levobupivacaine–esketamine in a propensity-matched cohort of 328 patients [76]; longer time to first PCA press and lower NRS with ropivacaine–esketamine [77,78]). In a 2×2 factorial trial, esketamine improved QoR independently of block type [25], and in non-intubated VATS low-dose esketamine plus paravertebral block improved mechanical pain thresholds, QoR-40, and reduced sufentanil/norepinephrine use [79]. Intravenous esketamine was non-inferior to ESPB for recovery quality after VATS, though ESPB provided better early coughing analgesia [80]. In PCIA after VATS lobectomy, esketamine-based PCIA improved pain and recovery quality versus sufentanil [81], and 0.03 mg/kg/h esketamine plus ICNB reduced acute pain and PONV [82]. A multicenter trial protocol (ChiCTR2000040012) was registered to evaluate acute and chronic post-thoracoscopy pain [83].
Table 2. Selected clinical trials of esketamine in thoracic/lung cancer surgery.
| PMID | Design / n | Population | Esketamine regimen | Key respiratory/PPC result | Other outcomes |
|---|---|---|---|---|---|
| 42760676 [15] | RCT, double-blind, n=80 | Thoracoscopic radical lung cancer resection | Perioperative esketamine (regimen per protocol) | PPC POD1 37.5% vs 72.5% (P=0.002); no diff POD3/7 | No diff in secondary outcomes |
| 41376989 [12] | RCT, 3-arm, n=145 | VATS | Low-dose vs high-dose vs control | ↑a/A, ↑OI, ↓RI/A-aDO₂; ↓PPC incidence (P<0.05) | ↓pain, less hemodynamic fluctuation; no dose-response clarity |
| 38322862 [13] | RCT, double-blind, n=80 | VATS lung resection | Postop infusion 0.75 µg/mL + sufentanil | ↓low minute ventilation (P=0.014); ↓PPC (P=0.039); ↓hypoxemia (P=0.003) | ↓POD2 pain; ↑sleep quality |
| 38597439 [22] | RCT, 4-arm, n=160 | Elderly thoracoscopic lung cancer | 0.5 mg/kg + limb ischemic preconditioning | ↓CC-16, SP-D, TNF-α; ↓infection/atelectasis; ↓LOS | Combination superior |
| 42545378 [23] | RCT, non-inferiority, n=126 | Thoracoscopic surgery | Intraoperative esketamine vs dexmedetomidine | Non-inferior P/F ratio; no PPC difference (P=0.86) | ↑QoR-15; ↓opioid |
| 42292822 [24] | RCT, n=144 | Elderly radical lung cancer surgery | 0.5 mg/kg + 0.25 mg/kg/h ± PCIA | — | ↑QoR-15 POD3 (P<0.001) |
| 41252770 [11] | RCT, 4 groups, n=60 | Mild-moderate COPD, VATS | 0.25 mg/kg ± dexmedetomidine | ↓Ppeak/Pplat, ↑Cdyn; ↓IL-6/IL-8/MDA; ↑IL-10/SOD | ↑PaO₂ (combination) |
| 41450534 [75] | RCT, double-blind, n=136 | Elderly thoracoscopic lung surgery | 0.25 mg/kg + 0.25 mg/kg/h | — | ↓moderate-severe pain (NNT 5.7); ↓sleep disturbance |
| 38522144 [51] | RCT, double-blind, n=129 | Non-cardiac thoracic surgery | 0.2 or 0.5 mg/kg single dose | — | ↑mood; ↓S100β/IL-6; ↑BDNF |
| 37009103 [52] | RCT, double-blind, n=156 | Thoracoscopic lung cancer | Intraop + PCIA ×48 h | — | ↓depression at 1 mo (1.3% vs 11.8%) |
| 40599293 [53] | RCT, double-blind, n=88 | Frail elderly lung cancer | 0.25 mg/kg + 0.125 mg/kg/h | — | ↓HAMD-17; ↑sleep; BDNF/5-HT changes |
| 41425495 [27] | RCT, n=80 | Elderly thoracoscopic lung cancer | Esketamine OFA | — | POCD 20% vs 42.5% (P=0.054); ↓reaction time |
| 41437743 [74] | RCT, single-blind, n (elderly) | Pulmonary lobectomy | 0.3 mg/kg/h | — | ↓POCD day 1/3; ↓tau; ↑Aβ42/40 |
| 41611566 [80] | RCT, non-inferiority, n=112 | VATS | 0.25 mg/kg + 0.25 mg/kg/h vs ESPB | — | QoR non-inferior; ESPB better early cough pain |
| 42092780 [10] | RCT, n=100 | Laparoscopic bariatric surgery | Esketamine-led OFA | PPC 26% vs 50% (RR 0.52; P=0.013); ↓hypoxemia (22% vs 42%) | ↓24-h opioid; nystagmus 56%; longer PACU |
4.3 Supporting non-thoracic evidence
The strongest PPC-specific signal outside thoracic surgery comes from the bariatric RCT (n = 100): esketamine-led OFA reduced PPC incidence from 50% to 26% (RR 0.52; 95% CI 0.30–0.89; P = 0.013), with a notable reduction in hypoxemia (22% vs 42%; P = 0.032) [10]. However, the 24-hour opioid reduction did not reach the prespecified clinical significance threshold (10 mg morphine-equivalent), nystagmus occurred in 56% of the esketamine group versus none in controls, and PACU stay was longer [10]. The obesity network meta-analysis (37 RCTs; 3,602 patients) likewise found ketamine/esketamine significantly reduced postoperative pulmonary complications, alongside opioid-sparing effects for several adjuvants [10]. A multimodal OFA meta-analysis of 14 RCTs (1,703 patients) found esketamine-containing OFA reduced PONV (RR 0.47; high certainty) and intraoperative hypotension (RR 0.29; high certainty) and reduced chronic postoperative pain in the two thoracic trials analyzed, with no between-group difference in 24- and 48-hour pain scores [44].
4.4 Pain, recovery, sleep, and psychological endpoints — the broadest and most consistent evidence
Beyond PPCs, esketamine’s perioperative benefits are replicated across many surgical populations. Meta-analyses show reduced postoperative fatigue at postoperative days 3 and 7 [84], reduced post-anesthetic shivering in cesarean delivery with a dose-response relationship (RR 0.29) but increased hallucination (RR 11.19) and nystagmus [38], reduced postoperative sleep disturbance on postoperative day 1 (OR 0.38) [85], improved subjective sleep quality (SMD −0.40) [86], and improved early quality of recovery without increased adverse events [70]. Randomized trials in gynecological laparoscopy and surgical abortion confirm the sleep-disturbance benefit [87,88]. These patient-centered and surrogate outcomes are the most robust part of the esketamine evidence base; they are also the outcomes most likely to be measured consistently across Chinese trials, in contrast to hard PPC composites.
4.5 Safety and adverse-effect signals
At subanesthetic perioperative doses, the controlled-trial adverse-event profile is generally acceptable: meta-analysis of 35 RCTs found no significant excess of nausea, agitation, dizziness, or hallucinations with low-dose intraoperative esketamine [37], and the OFA meta-analysis found no difference in nightmares/hallucinations [44]. Nevertheless, three signals merit attention. First, psychotomimetic/dissociative effects are dose-related and were documented in 8.5% of patients receiving esketamine added to a thoracic paravertebral block [76] and in esketamine-led OFA (nystagmus 56%) [10]. Second, hemodynamic effects — typically favorable in the elderly and cardiac patients — are not universal, and caution is warranted where chronotropy is critical [8,44]. Third, and most concerning for thoracic surgery, a large retrospective TriNetX analysis (7,972 propensity-matched pairs) found perioperative ketamine/esketamine exposure associated with increased 30-day postoperative atrial fibrillation/flutter (2.9% vs 2.2%; HR 1.33; 95% CI 1.10–1.62; P = 0.004), increased other arrhythmias (HR 1.60), and higher 30–90-day mortality (HR 1.54); the authors explicitly caution that the retrospective design and unmeasured confounding preclude causal inference [36]. This arrhythmia signal contrasts with a smaller RCT showing esketamine reduced postoperative delirium and inflammatory response after off-pump CABG [89] and with a cardiac-valve RCT of esketamine for delirium [28], and it requires prospective adjudication with detailed anesthetic and opioid dosing data [36].
5. Context: What Else Reduces PPCs, and How Much Can a Drug Add?
Interpreting esketamine’s PPC effects requires the comparison class. The prevention literature establishes a hierarchy of intervention efficacy (Table 4).
Non-pharmacologic and ventilatory strategies. A 2026 systematic review and meta-analysis of 255 trials (55,260 patients) in abdominal surgery found low FiO₂ to be the only intervention supported by high-certainty evidence for PPC reduction (RR 0.81; 95% CI 0.71–0.92), with moderate-certainty benefit for lung-protective ventilation (RR 0.66), physiotherapy (RR 0.55), analgesia (RR 0.73), and nutrition (RR 0.74); targeted blood pressure, restrictive fluids, and postoperative BiPAP showed no benefit [90]. In thoracic surgery, a meta-analysis of pre- and post-operative rehabilitation (23 studies, 2,068 participants) found preoperative interventions reduced PPCs (OR 0.32) and length of stay [91]; preoperative breathing exercises reduced PPCs (OR 0.37) and pneumonia in lung cancer resection [92]; prehabilitation meta-analyses (15–29 RCTs) consistently reduced PPCs (OR ~0.39–0.42) and improved functional capacity [93,94]; an ERAS-versus-conventional rehabilitation RCT after thoracoscopic lung cancer resection reduced atelectasis/pulmonary infections (P = 0.029) and ICU admission [95]; and goal-directed fluid therapy reduced PPCs in a thoracic meta-analysis [96]. Conversely, positive expiratory pressure devices showed no consistent PPC benefit (low certainty) [97], and incentive spirometry lacks general-population benefit outside higher-risk COPD patients [98]. Two landmark phase 3 ventilation trials were null on PPCs: PROTHOR (n = 2,200) found higher PEEP (10 cmH₂O) plus recruitment manoeuvres did not reduce PPCs versus lower PEEP (5 cmH₂O) (53.6% vs 56.4%; P = 0.155) and caused more intraoperative hypotension and arrhythmias [31]; and PRIME-AIR (n = 794; 751 analysed) found a perioperative lung-expansion bundle did not reduce PPC severity in moderate-to-high-risk open abdominal surgery [35]. Additional nulls include ventilation mode (volume- vs pressure-controlled) in lung resection (22% overall PPCs; P = 0.831) [32], driving-pressure-guided ventilation in thoracic surgery (40.5% vs 42.8%; P = 0.42) [30], and low tidal volume in major surgery (38% vs 39%; P = 0.64) [34]. Positive smaller trials exist (e.g., lung-protective ventilation in ARISCAT moderate-risk abdominal surgery reduced PPCs from 29.8% to 10.9% [99]; individualized PEEP in thoracoscopic lung surgery reduced PPCs from 42.1% to 13.2% [100]; pressure-controlled ventilation reduced PPCs versus volume-controlled in elderly Trendelenburg laparoscopy, 13.0% vs 32.1% [101]), but they are smaller and inconsistent with the phase 3 record. Sugammadex versus neostigmine has emerging evidence for reducing atelectasis/PPCs after VATS in meta-analysis and propensity-matched cohorts [102,103], and non-intubated VATS showed lower PPCs than intubated VATS in a randomized diaphragm-function trial (17.5% vs 33.8%; P = 0.019) and a large retrospective cohort (4.59% vs 23.45%) [104,105].
The salient lesson is that even large, mechanistically well-grounded perioperative interventions frequently fail to move hard PPC endpoints, and effect sizes in small single-center trials (including the esketamine literature) are often far larger than those seen at phase 3 scale [30,31,32,34,35]. Esketamine’s demonstrated contributions to oxygenation, mechanics, pain, sleep, mood, and recovery are real and reproducible; its incremental effect on composite PPC incidence, over modern lung-protective and ERAS care, remains unproven.
Table 4. Selected PPC-prevention interventions and their evidence.
| Intervention | Population | Effect on PPCs | Certainty/notes | Source |
|---|---|---|---|---|
| Low FiO₂ | Abdominal surgery | RR 0.81 (0.71–0.92) | High certainty | [90] |
| Lung-protective ventilation | Abdominal surgery | RR 0.66 (0.57–0.76) | Moderate certainty | [90] |
| Physiotherapy | Abdominal surgery | RR 0.55 (0.46–0.65) | Moderate certainty | [90] |
| Analgesia strategy | Abdominal surgery | RR 0.73 (0.64–0.84) | Moderate certainty | [90] |
| Preoperative exercise prehabilitation | Lung cancer surgery | OR/RR ~0.39–0.42 | Meta-analyses, consistent | [93,94] |
| Preoperative breathing exercises | Lung cancer resection | OR 0.37 | Meta-analysis | [92] |
| ERAS vs conventional rehab | Thoracoscopic lung cancer | ↓atelectasis/infection (P=0.029) | Single RCT | [95] |
| Individualized PEEP | Thoracoscopic lung surgery | 42.1% → 13.2% | Small RCT | [100] |
| Non-intubated vs intubated VATS | Lung surgery | 17.5% vs 33.8% (P=0.019) | RCT | [104] |
| Sugammadex vs neostigmine | VATS | OR 0.68 for overall PPCs | Meta-analysis | [102,103] |
| High PEEP + recruitment (PROTHOR) | Thoracic OLV | No benefit (53.6% vs 56.4%) | Phase 3 null | [31] |
| Lung-expansion bundle (PRIME-AIR) | Open abdominal | No benefit on severity | Phase 3 null | [35] |
| Ventilation mode | Lung resection | No benefit (P=0.831) | RCT null | [32] |
| Driving-pressure-guided | Thoracic surgery | No benefit (P=0.42) | RCT null | [30] |
| Low tidal volume | Major surgery | No benefit (P=0.64) | RCT null | [34] |
6. Synthesis: Does Esketamine Reduce PPCs After Radical Lung Cancer Surgery?
A defensible synthesis, graded against the available evidence, is as follows:
- There is a consistent, reproducible signal that esketamine improves early respiratory physiology in thoracic surgery. Across multiple independent RCTs, esketamine has improved oxygenation indices (a/A ratio, PaO₂/FiO₂, OI), reduced alveolar-arterial oxygen difference and respiratory index, improved dynamic compliance and airway pressures, reduced hypoxemia and low minute ventilation, and attenuated inflammatory and lung-injury biomarkers (IL-6, IL-8, TNF-α, CC-16, SP-D, MDA) [11,12,13,22,23]. This is the most robust part of the evidence.
- The specific claim of reduced PPC incidence is supported but fragile. The seed trial and several others report lower PPC rates [12,13,15], but the effect is often confined to the earliest postoperative window [15], is absent in the most rigorous active-comparator trial [23], and rests on small samples with undefined or heterogeneous PPC definitions [15].
- The most plausible mediator is opioid sparing and avoidance of opioid-induced respiratory depression. The bariatric RCT’s PPC reduction was accompanied by a hypoxemia-specific effect and by opioid reduction [10]; OFA consistently reduces PONV and respiratory depression relative to opioid-based anesthesia [42,44,45,46]; and the inflammatory benefits of OFA support a systemic mechanism [42].
- The evidence base is geographically concentrated and methodologically limited. Most thoracic RCTs are small, single-center, conducted in China, and use surrogate endpoints; meta-analyses reach positive conclusions for pain, quality of recovery, sleep, mood, and fatigue [37,69,70,84,85,86], but the PPC literature lacks a large multicenter trial with a prespecified validated composite endpoint and adequate follow-up.
- Any benefit must be interpreted against a backdrop of null phase 3 prevention trials. PROTHOR, PRIME-AIR, ventilation-mode, driving-pressure, and low-tidal-volume trials all failed to reduce PPCs [30,31,32,34,35], setting a realistic prior that a single pharmacologic adjunct will produce a small incremental effect at best, and that large apparent effects in small trials likely reflect instrument sensitivity and transient events.
Table 5. Summary effect estimates relevant to esketamine and PPCs.
| Outcome | Best available estimate | Source |
|---|---|---|
| PPC incidence POD1 (seed RCT) | 37.5% vs 72.5%; P=0.002 (n=80) | [15] |
| PPC incidence POD3/7 (seed RCT) | No significant difference | [15] |
| PPC incidence, bariatric OFA RCT | 26% vs 50%; RR 0.52 (0.30–0.89); P=0.013 | [10] |
| Hypoxemia, bariatric OFA RCT | 22% vs 42%; P=0.032 | [10] |
| PPC, active comparator (esk vs dexmed) | No difference (P=0.86) | [23] |
| PPC, obesity network meta-analysis | Ketamine/esketamine significantly reduced POPCs | [10] |
| Resting pain 4 h (low-dose IV esketamine) | MD −1.40; P<0.0001 (35 RCTs, n=3,831) | [37] |
| Rescue analgesia | RR 0.52; P=0.0001 | [37] |
| Quality of recovery POD1–2 | SMD 0.63 and 0.56 | [70] |
| Sleep disturbance POD1 | OR 0.38 (0.29–0.50) | [85] |
| Depression at 1 month (thoracic RCT) | 1.3% vs 11.8%; P=0.018 | [52] |
| POAF after VATS (retrospective) | HR 1.33 (1.10–1.62) | [36] |
7. Clinical Implications
For the practicing thoracic anesthesiologist, the evidence supports esketamine as a reasonable opioid-sparing component of multimodal thoracic anesthesia, particularly in patients at elevated risk of opioid-related respiratory depression, those undergoing opioid-free or low-opioid protocols, and those in whom quality of recovery, early mobilization, sleep, or mood are prioritized [8,10,23,24,25,26,37,44,70,75,85]. Its use should be dose-conscious (commonly 0.2–0.5 mg/kg bolus with 0.125–0.25 mg/kg/h infusion, or 0.015–0.03 mg/kg/h in PCIA) [22,23,24,25,26,27,28], with awareness of psychotomimetic/dissociative effects and the retrospective atrial-fibrillation signal [36,37,76]. Esketamine is best deployed within an optimized perioperative bundle — lung-protective ventilation, neuromuscular monitoring and reversal, low-FiO₂ where safe, prehabilitation and physiotherapy, ERAS pathways, and effective regional analgesia — rather than as a stand-alone PPC prophylactic, because those bundle elements carry the strongest or most consistent evidence and even they produce modest, sometimes null, hard-endpoint effects [30,31,32,34,35,90,91,92,93,94,95,96,102,103,104]. Finally, clinicians should be explicit with patients and colleagues that the reduction of early, often transient PPC surrogates is the best-supported claim, not prevention of pneumonia, respiratory failure, or death [15,23].
8. LIMITATIONS
This review has several important limitations and should be read with them in mind.
- Abstract-level evidence. All statistics were extracted from PubMed abstracts and record metadata; full texts were not systematically reviewed. Several trials report composite endpoints and subgroup analyses that could alter interpretation; where abstracts did not report numbers (e.g., several Chinese-language RCTs), findings are described qualitatively and no statistics are attributed.
- Definitional heterogeneity. The PPC endpoint is not standardized across the included trials [3,33,54,55,56,57]. The seed trial and many supporting trials do not specify their PPC definition or severity instrument, which prevents pooled quantitative synthesis and inflates the risk of comparing unlike outcomes [15].
- Small trials and single-center concentration. Most thoracic esketamine RCTs are small (n = 60–160), single-center, and epidemiologically concentrated in China; publication and small-study effects cannot be excluded. No large, multicenter phase 3 esketamine PPC trial exists.
- Early and transient endpoints. The seed trial’s benefit is confined to postoperative day 1 and vanishes thereafter, and several positive trials use oxygenation or minute-ventilation surrogates rather than adjudicated clinical PPCs [12,13,15]. Surrogate improvement is not equivalent to prevention of pneumonia, respiratory failure, or mortality [23].
- Confounding in observational safety data. The atrial-fibrillation/flutter signal derives from a retrospective administrative database with potential unmeasured confounding, residual indication bias, and no detailed drug-dosing information; it is a hypothesis, not a causal finding [36].
- Comparability of esketamine and ketamine. Much of the mechanistic and OFA literature studies racemic ketamine or mixed ketamine/esketamine cohorts; enantiomer-specific effects and dose-equivalence are not fully resolved [8,9].
- Nanning of efficacy by comparator choice. Trials compare esketamine with placebo/saline, with sufentanil-based analgesia, with dexmedetomidine, or with regional blocks; these are not interchangeable, and the active-comparator trial showing no PPC difference is particularly instructive [23].
- Translation gap in preclinical mechanisms. The lung-protective pathways (NMDAR2A–NF-κB/NLRP3–GSDMD, caspase-11, TLR4–NF-κB–NLRP3, TGF-β–Smad3, gut–lung axis) are compelling but are derived from rodent and cell models; their clinical dose-response and relevance to surgical PPCs are unestablished [16,17,18,19,20,21].
- Tumor-biology uncertainty. Preclinical antiproliferative effects and GRIN2D-mediated lung cancer growth raise theoretical questions about NMDA modulation and tumor biology that cannot be resolved with available clinical data and should not influence practice [71,72].
- Language and indexing limitations. Several included trials are published in Chinese-language journals with English abstracts; nuances of randomization, blinding, and outcome ascertainment may be incompletely captured. Search was limited to English-indexed records and ClinicalTrials.gov, so non-indexed registry activity in other databases may be missed.
- Verification scope. Every cited PMID was mechanically verified via NCBI E-utilities esummary on 2026-10-05, but verification confirms record existence and bibliographic accuracy, not the internal validity of any study.
9. Open Questions, Research Agenda, and Registry Landscape
Several questions are unresolved and define the research agenda.
Does esketamine reduce hard, adjudicated PPCs at scale? The decisive experiment is a multicenter RCT of perioperative esketamine versus placebo added to protocolized lung-protective ventilation and ERAS care in high-risk lung resection, with a validated composite PPC endpoint (StEP-COMPAC or EPCO), prespecified severity grading, 30-day follow-up, and adequate power. Without such a trial, the seed trial’s large day-1 effect cannot be distinguished from instrument sensitivity [15,33]. Which PPC definition and window should be standard? Adoption of StEP-COMPAC/EPCO definitions with explicit grade and follow-up duration would allow meta-analysis of esketamine and other interventions [54,55]. What is the optimal dose and route, and does a dose-response exist? Trials have used 0.1–0.5 mg/kg boluses, 0.125–0.25 mg/kg/h infusions, and PCIA doses of 0.015–0.03 mg/kg/h with inconsistent dose-response findings [8,37,75,76,82]. Dose-finding studies powered on respiratory endpoints are needed. Are the arrhythmia and psychotomimetic signals real and clinically important? The retrospective POAF signal [36] and dose-related dissociative effects [10,37,76] require prospective capture with continuous rhythm monitoring, standardized psychiatric assessment, and detailed dosing. Does opioid avoidance, rather than esketamine itself, mediate the benefit? Head-to-head OFA trials comparing esketamine-based OFA with equipotent opioid-sparing but non-ketamine regimens would isolate the contribution of NMDA antagonism from opioid dose reduction [10,42,44,45,46]. Do the preclinical mechanisms translate at clinical doses? Biomarker-embedded trials (IL-6, IL-8, TNF-α, CC-16, SP-D, RAGE) with dose-randomization could test whether the rodent pathways operate in patients [11,16,17,18,19,22]. Does esketamine affect oncologic outcomes? Long-term recurrence and survival follow-up of thoracic esketamine trials — rarely reported — would address the theoretical NMDA/tumor-biology question and are ethically warranted [71,72].
Registry landscape (ClinicalTrials.gov, accessed 2026-10-05). Multiple registered studies address esketamine in thoracic or pulmonary contexts, including: NCT05458453 (exploratory esketamine after thoracoscopic surgery, completed) [13]; NCT06310785 (esketamine anesthesia in thoracic surgery, completed); NCT06822088 (esketamine, oxygenation, and quality of recovery in thoracoscopic surgery, not yet recruiting); NCT07064408 (subanesthetic esketamine for hemodynamic stability/recovery in elderly thoracic surgery, completed); NCT05341375 (thoracic paravertebral block plus S-ketamine, completed); NCT05016128 (intraoperative S-ketamine to prevent postoperative hyperalgesia in VATS, status unknown); NCT04745286 (small-dose S-ketamine and anesthesia-induced atelectasis, status unknown) [106]; NCT06367218 (opioid-free combined anesthesia for VATS, recruiting); and NCT06467513 (esketamine hydrochloride and pulmonary complications, status unknown). Most are small and none appears designed as a definitive multicenter PPC-outcome trial. This registry landscape reinforces the central conclusion: the hypothesis is active and plausible, but the definitive trial has not yet been done.
10. Conclusions
Esketamine has a coherent pharmacologic and preclinical rationale for lung protection, a robust and reproducible record of improving early respiratory physiology, oxygenation, pain, quality of recovery, sleep, and mood after thoracic surgery, and at least one non-thoracic RCT and one network meta-analysis showing reduced PPCs [10,11,12,13,15,16,17,18,19,20,21,22,23,24,25,26,37,44,70,75,85]. The seed trial’s finding — a halving of day-1 PPCs with no downstream or secondary benefit — is therefore biologically plausible and consistent with an opioid-sparing, hypoxemia-attenuating mechanism, but it is not yet a reliable basis for claiming that esketamine prevents clinically meaningful PPCs after radical lung cancer surgery [10,15,23]. The absence of a large, multicenter, validated-endpoint trial, the heterogeneity of PPC definitions, the early/transient nature of the effect, and the string of null phase 3 PPC-prevention trials all counsel caution [30,31,32,33,34,35]. The defensible current position is that esketamine is a reasonable, low-to-intermediate-risk opioid-sparing adjunct within a comprehensive thoracic ERAS and lung-protective strategy, with the strongest evidence supporting improved recovery and respiratory physiology rather than prevention of pneumonia, respiratory failure, or death; prospective surveillance of psychotomimetic and arrhythmic effects is warranted, and a definitive multicenter PPC trial remains the field’s highest-priority unmet need [8,23,36,37,90].
References
- Kaufmann K, Heinrich S. Minimizing postoperative pulmonary complications in thoracic surgery patients. Curr Opin Anaesthesiol. 2021;34(1):13-19. doi:10.1097/ACO.0000000000000945. PMID: 33315642.
- Hardt K, Maegele M, Limper U. Critical care challenges after thoracic surgery for carcinoma and pulmonary metastases – avoiding postoperative complications. Curr Opin Crit Care. 2025;31(6):766-773. doi:10.1097/MCC.0000000000001333. PMID: 41165272.
- Gallart L, Canet J. Post-operative pulmonary complications: Understanding definitions and risk assessment. Best Pract Res Clin Anaesthesiol. 2015;29(3):315-30. doi:10.1016/j.bpa.2015.10.004. PMID: 26643097.
- Yu G, Lin R. The Impact of Postoperative Pulmonary Complications on Short-Term Health-Related Quality of Life in Older Adults (Aged 60-80 Years) Undergoing Surgery for Early-Stage Lung Cancer. World J Surg. 2025;49(9):2344-2353. doi:10.1002/wjs.70040. PMID: 40804034.
- Baar W, Semmelmann A, Anselm F, Loop T, Heinrich S, For The Working Group Of The German Thorax Registry. Risk Factors for Postoperative Pulmonary Complications in Patients Undergoing Thoracotomy for Indications Other than Primary Lung Cancer Resection: A Multicenter Retrospective Cohort Study from the German Thorax Registry. J Clin Med. 2025;14(5). doi:10.3390/jcm14051565. PMID: 40095485.
- Feeney A, Papakostas GI. Pharmacotherapy: Ketamine and Esketamine. Psychiatr Clin North Am. 2023;46(2):277-290. doi:10.1016/j.psc.2023.02.003. PMID: 37149345.
- McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251. PMID: 33726522.
- Mion G, Himmelseher S. Esketamine: Less Drowsiness, More Analgesia. Anesth Analg. 2024;139(1):78-91. doi:10.1213/ANE.0000000000006851. PMID: 38295061.
- Vekhova KA, Namiot ED, Jonsson J, Schiöth HB. Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations. Clin Pharmacol Ther. 2025;117(2):374-386. doi:10.1002/cpt.3478. PMID: 39428602.
- Sun HL, Liu HY, Jiang CQ, Wu ZF, Wang WL, Yang SQ, et al. Esketamine-led opioid-free anaesthesia reduces postoperative pulmonary complications in bariatric surgery patients: a prospective randomized controlled trial. BMC Anesthesiol. 2026;26(1). doi:10.1186/s12871-026-03886-w. PMID: 42092780.
- Zhang XQ, Liu Y, Xie WX, Mao Y, Liu A, Huang S, et al. Effects of esketamine combined with dexmedetomidine on oxidative stress and lung function during one-lung ventilation in patients with mild to moderate COPD undergoing thoracoscopic surgery. Int Immunopharmacol. 2026;168(Pt 2):115860. doi:10.1016/j.intimp.2025.115860. PMID: 41252770.
- Yang F, Mu T, Xiong W, Yin X, Ran W, Yuan R, et al. Lung-protective effects of esketamine in patients undergoing video-assisted thoracoscopic surgery: a randomized controlled trial. J Thorac Dis. 2025;17(11):9696-9710. doi:10.21037/jtd-2025-999. PMID: 41376989.
- Fu M, Xu R, Chen G, Zheng X, Shu B, Huang H, et al. Postoperative esketamine improves ventilation after video-assisted thoracoscopic lung resection: A double-blinded randomized controlled trial. Heliyon. 2024;10(3):e25100. doi:10.1016/j.heliyon.2024.e25100. PMID: 38322862.
- Qi Y, Zhou M, Zheng W, Dong Y, Li W, Wang L, et al. Effect of S-Ketamine on Postoperative Nausea and Vomiting in Patients Undergoing Video-Assisted Thoracic Surgery: A Randomized Controlled Trial. Drug Des Devel Ther. 2024;18:1189-1198. doi:10.2147/DDDT.S449705. PMID: 38645990.
- Huang J, Wang J, Gu X, Pang P, Zhang L. Effect of esketamine on postoperative pulmonary complications after radical surgery for lung cancer: A randomized double-blind controlled trial. Medicine (Baltimore). 2026;105(38):e50571. doi:10.1097/MD.0000000000050571. PMID: 42760676.
- Hu Q, Peng L, Chen XY, Zhu YC, Liang Zhang, Lu MY, et al. Esketamine protects against LPS-induced septic lung injury via NMDA receptor and NF-κB/NLRP3/Caspase-1/GSDMD pathway. Int Immunopharmacol. 2026;186:117105. doi:10.1016/j.intimp.2026.117105. PMID: 42401091.
- Bao Y, Feng Z, Niu Y, Hu Q, Liu H, Zhang H, et al. Esketamine mitigates endotoxin-induced acute lung injury by suppressing caspase-11-driven pyroptosis. BMC Anesthesiol. 2025;25(1):356. doi:10.1186/s12871-025-03220-w. PMID: 40691531.
- Wang M, Ma Q, Wang W, Cun J, Wen H. Esketamine Reduces Lung Injury Caused by Limb Ischemia-Reperfusion by Regulating Oxidative Stress via the TLR4/NF-κB/NLRP3 Pathway. Endocr Metab Immune Disord Drug Targets. 2026;26:e18715303393744Pages. doi:10.2174/0118715303393744250423100211. PMID: 40304322.
- Haolan, Wang Y, Gao Y, Liu Y, Deng B, Li P, et al. Esketamine attenuated sepsis-induced organ injury in mice via the TGF-β-Smad3 signaling pathway. Cytokine. 2026;203:157163. doi:10.1016/j.cyto.2026.157163. PMID: 42102747.
- Zhao X, Zhang X, Yuan S, Hashimoto K, Zhang J. Pleiotropic modulation of the gut-brain-lung axis by ketamine and its enantiomers. Mol Psychiatry. 2026;31(9):5014-5030. doi:10.1038/s41380-026-03590-8. PMID: 41974884.
- Liu A, Zhang XQ, Guo JX, Wen QY, Dai K, Zheng WJ, et al. Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation. J Neuroinflammation. 2026;23(1):68. doi:10.1186/s12974-026-03699-1. PMID: 41572340.
- Zhou H, Wei J, Yang Z, Zhou M, Pan Y, Chen J, et al. The esketamine-based multimodal low-opioid anaesthesia improves quality of recovery in elderly patients undergoing radical lung cancer surgery: a randomized controlled trial. Front Pharmacol. 2026;17:1769225. doi:10.3389/fphar.2026.1769225. PMID: 42292822.
- Feng R, Wang Z, Yang Y, Wang Q, Zhao Y, Qian X, et al. Esketamine versus dexmedetomidine for oxygenation and postoperative quality of recovery in thoracoscopic surgery: a randomized, double-blind, non-inferiority controlled trial. J Anesth. 2026. doi:10.1007/s00540-026-03853-2. PMID: 42545378.
- Chen X, Zhu Y, Peng K, Wang Q, Feng C. Effect of S-ketamine on the intraoperative Surgical Pleth Index in patients undergoing video-assisted thoracoscopic surgery: a single-center randomized controlled clinical trial. J Int Med Res. 2023;51(9):3000605231198386. doi:10.1177/03000605231198386. PMID: 37694976.
- Hu JH, Zhong ZZ, Shi HJ, Wang J, Chen S, Shan XS, et al. Esketamine vs. placebo combined with erector spinae plane block vs. intercostal nerve block on quality of recovery following thoracoscopic lung resection: a randomized controlled factorial trial. Int J Surg. 2025;111(1):677-685. doi:10.1097/JS9.0000000000002060. PMID: 39172717.
- Cheng X, Wang H, Diao M, Jiao H. Effect of S-ketamine on Postoperative Quality of Recovery in Patients Undergoing Video-Assisted Thoracic Surgery. J Cardiothorac Vasc Anesth. 2022;36(8 Pt B):3049-3056. doi:10.1053/j.jvca.2022.04.028. PMID: 35613989.
- Zhan Y, Liu Z, Meng S, Luo M, Huang Z, Wang L. The Effect of Opioid-Free Anesthesia with Esketamine on Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Thoracoscopic Surgery: A Prospective, Randomized, Controlled Trial. Drug Des Devel Ther. 2025;19:11227-11244. doi:10.2147/DDDT.S553370. PMID: 41425495.
- Xiong X, Shao Y, Chen D, Chen B, Lan X, Shi J. Effect of Esketamine on Postoperative Delirium in Patients Undergoing Cardiac Valve Replacement with Cardiopulmonary Bypass: A Randomized Controlled Trial. Anesth Analg. 2024;139(4):743-753. doi:10.1213/ANE.0000000000006925. PMID: 38446699.
- Carron M, Tamburini E, Linassi F, Pettenuzzo T, Boscolo A, Navalesi P. Efficacy of nonopioid analgesics and adjuvants in multimodal analgesia for reducing postoperative opioid consumption and complications in obesity: a systematic review and network meta-analysis. Br J Anaesth. 2024;133(6):1234-1249. doi:10.1016/j.bja.2024.08.009. PMID: 39366846.
- Park M, Yoon S, Nam JS, Ahn HJ, Kim H, Kim HJ, et al. Driving pressure-guided ventilation and postoperative pulmonary complications in thoracic surgery: a multicentre randomised clinical trial. Br J Anaesth. 2023;130(1):e106-e118. doi:10.1016/j.bja.2022.06.037. PMID: 35995638.
- Writing Committee, Steering Committee, PROTHOR Collaborative Group, PROtective VEntilation Network (PROVE Network) for the Clinical Trial Network of the European Society of Anaesthesiology and Intensive Care. Effects of intraoperative higher versus lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR): a multicentre, international, randomised, controlled, phase 3 trial. Lancet Respir Med. 2026;14(1):17-28. doi:10.1016/S2213-2600(25)00330-3. PMID: 41240959.
- Li XF, Jin L, Yang JM, Luo QS, Liu HM, Yu H. Effect of ventilation mode on postoperative pulmonary complications following lung resection surgery: a randomised controlled trial. Anaesthesia. 2022;77(11):1219-1227. doi:10.1111/anae.15848. PMID: 36066107.
- Ferrando-Ortolá C, iPROVE Research Network Group for the PEALS study. Postoperative pulmonary complications in emergency abdominal surgery. A prospective international cohort study. Anaesth Crit Care Pain Med. 2025;44(5):101560. doi:10.1016/j.accpm.2025.101560. PMID: 40412513.
- Karalapillai D, Weinberg L, Peyton P, Ellard L, Hu R, Pearce B, et al. Effect of Intraoperative Low Tidal Volume vs Conventional Tidal Volume on Postoperative Pulmonary Complications in Patients Undergoing Major Surgery: A Randomized Clinical Trial. JAMA. 2020;324(9):848-858. doi:10.1001/jama.2020.12866. PMID: 32870298.
- Fernandez-Bustamante A, Parker RA, Frendl G, Lee JW, Nagrebetsky A, Grecu L, et al. Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2025;13(5):447-459. doi:10.1016/S2213-2600(25)00040-2. PMID: 40020692.
- Hung KC, Yu TS, Lai YC, Yu CH, Wu JY, Tsai WW, et al. Perioperative Ketamine Exposure and Postoperative Atrial Fibrillation/Flutter Risk After Video-Assisted Thoracoscopic Surgery: A Multi-Institutional Study. Drug Des Devel Ther. 2025;19:11173-11185. doi:10.2147/DDDT.S569143. PMID: 41425499.
- Majeed E, Rafique I, Inam K, Majeed F. Efficacy of intraoperative low dose intravenous Esketamine for acute postoperative pain control: Meta-analysis of randomized controlled trials. J Clin Anesth. 2026;114:112278. doi:10.1016/j.jclinane.2026.112278. PMID: 42492373.
- Yang K, Liu Q, Zhang L, Wang L, Xiong F, Song J, et al. Efficacy and safety of ketamine and esketamine for the prevention of postanesthetic shivering in cesarean delivery: a systematic review and meta-analysis. Front Med (Lausanne). 2026;13:1845684. doi:10.3389/fmed.2026.1845684. PMID: 42434003.
- Li C, Shi J, Wei S, Jia H. Potential ‘anti-cancer’ effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells. Eur J Med Res. 2023;28(1):517. doi:10.1186/s40001-023-01511-x. PMID: 37968758.
- Feng G, Jia Y, Zhao G, Meng F, Wang T. Risk factors for postoperative pulmonary complications in elderly patients undergoing video-assisted thoracoscopic surgery lobectomy under general anesthesia: a retrospective study. BMC Surg. 2024;24(1):153. doi:10.1186/s12893-024-02444-w. PMID: 38745149.
- Chikkala RKP, Pratyusha AC, Durga P, Patlolla P, Ponduru S, Rajasekhar M, et al. Validation of the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) Score for Predicting Postoperative Pulmonary Complications After Laparotomy in an Indian Population in the Present Era: A Retrospective Study. Cureus. 2025;17(9):e92743. doi:10.7759/cureus.92743. PMID: 41122551.
- Dai J, Li S, Zheng R, Li J. Effect of esketamine on inflammatory factors in opioid-free anesthesia based on quadratus lumborum block: A randomized trial. Medicine (Baltimore). 2023;102(37):e34975. doi:10.1097/MD.0000000000034975. PMID: 37713895.
- Fan Q, Luo J, Zhou Q, Zhang Y, Zhang X, Li J, et al. Esketamine opioid-free intravenous anesthesia versus opioid intravenous anesthesia in spontaneous ventilation video-assisted thoracic surgery: a randomized controlled trial. Front Oncol. 2023;13:1145953. doi:10.3389/fonc.2023.1145953. PMID: 37324000.
- Fang Y, Gao M, Wang X, Zheng B, He M, Zeng X, et al. Multimodal opioid-free anesthesia containing esketamine versus opioid-based anesthesia: a systematic review and meta-analysis. BMC Anesthesiol. 2026;26(1). doi:10.1186/s12871-026-03975-w. PMID: 42243697.
- Feng CD, Xu Y, Chen S, Song N, Meng XW, Liu H, et al. Opioid-free anaesthesia reduces postoperative nausea and vomiting after thoracoscopic lung resection: a randomised controlled trial. Br J Anaesth. 2024;132(2):267-276. doi:10.1016/j.bja.2023.11.008. PMID: 38042725.
- Larue A, Jacquet-Lagrèze M, Ruste M, Tronc F, Fellahi JL. Opioid-free anaesthesia for video-assisted thoracoscopic surgery: A retrospective cohort study with propensity score analysis. Anaesth Crit Care Pain Med. 2022;41(4):101089. doi:10.1016/j.accpm.2022.101089. PMID: 35490860.
- Amati AL, Negruta N, Ebert R, Kümmel N, Fritzenwanker M, Wolff M, et al. The underestimated burden of postoperative pulmonary complications in emergency laparotomy: a propensity score-matched analysis. Front Med (Lausanne). 2025;12:1733029. doi:10.3389/fmed.2025.1733029. PMID: 41473167.
- Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):139-148. doi:10.1001/jamapsychiatry.2017.3739. PMID: 29282469.
- Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428-438. doi:10.1176/appi.ajp.2019.19020172. PMID: 31109201.
- Janik A, Qiu X, Lane R, Popova V, Drevets WC, Canuso CM, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(9):877-887. doi:10.1001/jamapsychiatry.2025.1317. PMID: 40601310.
- Luo T, Deng Z, Ren Q, Mu F, Zhang Y, Wang H. Effects of esketamine on postoperative negative emotions and early cognitive disorders in patients undergoing non-cardiac thoracic surgery: A randomized controlled trial. J Clin Anesth. 2024;95:111447. doi:10.1016/j.jclinane.2024.111447. PMID: 38522144.
- Gan SL, Long YQ, Wang QY, Feng CD, Lai CX, Liu CT, et al. Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: A randomized controlled trial. Front Psychiatry. 2023;14:1128406. doi:10.3389/fpsyt.2023.1128406. PMID: 37009103.
- Zhang C, Yan Y, Ma J, Wang K, Liu D, Zhang Y, et al. [Esketamine Alleviates Postoperative Depressive Symptoms in Frail Elderly Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer: A Randomized Double-Blind Controlled Trial]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2025;56(2):506-513. doi:10.12182/20250360202. PMID: 40599293.
- Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Pelosi P, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol. 2015;32(2):88-105. doi:10.1097/EJA.0000000000000118. PMID: 25058504.
- Li S, Lu Y, Zhang H, Ma C, Xiao H, Liu Z, et al. Integrating StEP-COMPAC definition and enhanced recovery after surgery status in a machine-learning-based model for postoperative pulmonary complications in laparoscopic hepatectomy. Anaesth Crit Care Pain Med. 2024;43(6):101424. doi:10.1016/j.accpm.2024.101424. PMID: 39278548.
- Canet J, Gallart L, Gomar C, Paluzie G, Vallès J, Castillo J, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010;113(6):1338-50. doi:10.1097/ALN.0b013e3181fc6e0a. PMID: 21045639.
- Agostini P, Naidu B, Cieslik H, Rathinam S, Bishay E, Kalkat MS, et al. Comparison of recognition tools for postoperative pulmonary complications following thoracotomy. Physiotherapy. 2011;97(4):278-83. doi:10.1016/j.physio.2010.11.007. PMID: 22051583.
- Mazo V, Sabaté S, Canet J, Gallart L, de Abreu MG, Belda J, et al. Prospective external validation of a predictive score for postoperative pulmonary complications. Anesthesiology. 2014;121(2):219-31. doi:10.1097/ALN.0000000000000334. PMID: 24901240.
- Yan Y, Wang X, Li S, Zhao J, Zhou G, Zhong G, et al. Postoperative pulmonary complications after surgery for spinal metastases from lung cancer: a six-center risk analysis and external validation of three established risk scores. Spine J. 2026. doi:10.1016/j.spinee.2026.07.016. PMID: 42476194.
- Bevilacqua Filho CT, Schmidt AP, Felix EA, Bianchi F, Guerra FM, Andrade CF. Risk factors for postoperative pulmonary complications and prolonged hospital stay in pulmonary resection patients: a retrospective study. Braz J Anesthesiol. 2021;71(4):333-338. doi:10.1016/j.bjane.2021.02.003. PMID: 34229858.
- Xu M, Sun J, Sun M. Effect of hypoalbuminemia on postoperative pulmonary complications after thoracoscopic anatomical lung resection: a retrospective cohort study. PeerJ. 2026;14:e21456. doi:10.7717/peerj.21456. PMID: 42299149.
- Garelli V, Abellan C, Othenin-Girard A, Gunga Z, Abdurashidova T, Botteau C, et al. Incidence, patterns, and factors associated with postoperative pulmonary complications in an ERAS cardiac surgery program: a 500-patient cohort study. J Anesth Analg Crit Care. 2026;6(1). doi:10.1186/s44158-026-00402-x. PMID: 42104447.
- Kokotovic D, Degett TH, Ekeloef S, Burcharth J. The ARISCAT score is a promising model to predict postoperative pulmonary complications after major emergency abdominal surgery: an external validation in a Danish cohort. Eur J Trauma Emerg Surg. 2022;48(5):3863-3867. doi:10.1007/s00068-021-01826-6. PMID: 35050387.
- Zhang W, Gao Y, Li S, Huang Y, Guo M, Wu Z, et al. Comparative Evaluation of Risk Scores for Predicting Postoperative Pulmonary Complications. Respir Care. 2026;71(7):714-722. doi:10.1177/19433654261424879. PMID: 41784103.
- Huang Z, Han Y, Zhuang H, Jiang J, Zhou C, Yu H. Prediction models for postoperative pulmonary complications: a systematic review and meta-analysis. Br J Anaesth. 2025;135(5):1415-1427. doi:10.1016/j.bja.2025.04.025. PMID: 40473567.
- Zhou Y, Wang H, Lu D, Jiang T, Huang Z, Wang F, et al. Development and validation of a nomogram for predicting postoperative pulmonary complications in older patients undergoing noncardiac thoracic surgery: a prospective, bicentric cohort study. BMC Geriatr. 2025;25(1):169. doi:10.1186/s12877-025-05791-2. PMID: 40082767.
- Liu J, Xin S, Yang Y, Sun Q, Qi X, Hou L, et al. Association between preoperative inflammatory biomarkers and postoperative pulmonary complications in stage I-II non-small cell lung cancer: a retrospective study. Front Med (Lausanne). 2026;13:1833302. doi:10.3389/fmed.2026.1833302. PMID: 42440635.
- Dorland G, Saadat W, van Meenen DMP, Neto AS, Hiesmayr M, Hollmann MW, et al. Association of preoperative smoking with the occurrence of postoperative pulmonary complications: A post hoc analysis of an observational study in 29 countries. J Clin Anesth. 2025;104:111856. doi:10.1016/j.jclinane.2025.111856. PMID: 40373497.
- Wang X, Lin C, Lan L, Liu J. Perioperative intravenous S-ketamine for acute postoperative pain in adults: A systematic review and meta-analysis. J Clin Anesth. 2021;68:110071. doi:10.1016/j.jclinane.2020.110071. PMID: 33007645.
- Hung KC, Kao CL, Ho CN, Hsing CH, Chang YJ, Wang LK, et al. The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trials. Br J Anaesth. 2024;132(6):1293-1303. doi:10.1016/j.bja.2024.03.012. PMID: 38614917.
- Wang Y, Li W, Jia L, Shen J, Li C, Jia H. The Early Effects of Esketamine on the Tumor Metastatic Microenvironment in Postoperative Lung Cancer Patients. Clin Respir J. 2025;19(8):e70108. doi:10.1111/crj.70108. PMID: 40808216.
- Lv Y, Bu X, Du Z, Zhang Y, Si Y, Shi H, et al. Promotion of lung cancer growth via glutamate ionotropic receptor N-methyl-D-aspartate-type subunit 2D (GRIN2D). J Thorac Dis. 2026;18(1):36. doi:10.21037/jtd-2025-1-2538. PMID: 41660435.
- Xu Q, Han J. Comment on: Effects of esketamine combined with dexmedetomidine on oxidative stress and lung function during one-lung ventilation in patients with mild to moderate COPD undergoing thoracoscopic surgery. Int Immunopharmacol. 2026;168(Pt 2):115932. doi:10.1016/j.intimp.2025.115932. PMID: 41319566.
- Li X, Mao H, Luo J, Jiang W, Li P, Zhou L, et al. Effects of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Pulmonary Lobectomy: A Randomised, Single-Blind Controlled Clinical Trial. Actas Esp Psiquiatr. 2025;53(6):1320-1331. doi:10.62641/aep.v53i6.2044. PMID: 41437743.
- Zhao H, Liu Z, Zhang Y, Liu M, Ning Y, Gao D, et al. Effects of Intravenous Subanesthetic-Dose Esketamine on Early Postoperative Pain in Elderly Patients Undergoing Thoracoscopic Lung Surgery: A Randomized Double-Blind Controlled Trial. Drug Des Devel Ther. 2025;19:11289-11305. doi:10.2147/DDDT.S565937. PMID: 41450534.
- Jing Y, Jiang X, Hu B, Wang Y, Song B, Han C. Esketamine as an Adjuvant to Levobupivacaine in Thoracic Paravertebral Block for Thoracoscopic Lung Cancer Surgery: A Retrospective Propensity Score-Matched Cohort Study. J Pain Res. 2026;19:586352. doi:10.2147/JPR.S586352. PMID: 42504177.
- Yang Q, Luo Q, Cheng L, Yang ZX, Rao LH, Cheng F, et al. Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer. J Perianesth Nurs. 2025;40(5):1238-1244. doi:10.1016/j.jopan.2025.01.012. PMID: 40434336.
- Wen J, Zhou G, Bin Y, Zeng Y, Tan D, Zhang J. Ropivacaine combined with esketamine in ultrasound-guided thoracic paravertebral nerve block in lung cancer patients undergoing thoracoscopic radical surgery. Discov Oncol. 2025;16(1):1053. doi:10.1007/s12672-025-02762-2. PMID: 40498250.
- Zhang R, Luo Z, Zhang H, Wang Q, Luo C, He J, et al. The Effects of Low-Dose Esketamine Combined with Paravertebral Block on Postoperative Hyperalgesia and Enhanced Recovery in Non-Intubated Video-Assisted Thoracic Surgery: A Randomized Controlled Trial. Drug Des Devel Ther. 2025;19:7033-7043. doi:10.2147/DDDT.S531414. PMID: 40837277.
- Liu Z, Zhao H, Ning Y, Zhang Y, Liu M, Hui K, et al. Intravenous Esketamine Versus Erector Spinae Plane Block for Postoperative Recovery Quality Following Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Non-Inferiority Trial. J Cardiothorac Vasc Anesth. 2026;40(6):1766-1776. doi:10.1053/j.jvca.2025.12.030. PMID: 41611566.
- Bi R, Zhang J, Liu R, Li L, Su Y, Xu M, et al. Effect of esketamine-based patient-controlled intravenous analgesia on postoperative pain and quality of recovery after video-assisted thoracoscopic lobectomy: A prospective, double-blind, randomized controlled trial. PLoS One. 2026;21(1):e0340864. doi:10.1371/journal.pone.0340864. PMID: 41592015.
- Zhou M, Qi Y, Zhou F, Wu H, Chen J, Wang L, et al. Esketamine-based PCIA combined with intercostal nerve block for acute pain after lobectomy: a randomized controlled trial. Front Pharmacol. 2026;17:1746121. doi:10.3389/fphar.2026.1746121. PMID: 41859335.
- Lei Y, Liu H, Xia F, Gan S, Wang Y, Huo W, et al. Effects of Esketamine on Acute and Chronic Pain After Thoracoscopy Pulmonary Surgery Under General Anesthesia: A Multicenter-Prospective, Randomized, Double-Blind, and Controlled Trial. Front Med (Lausanne). 2021;8:693594. doi:10.3389/fmed.2021.693594. PMID: 34568362.
- Al Subhi M, Al Yousufi M, Alnajdi H, Al-Balushi A, Al Alawi IK, Al Abri S, et al. Effect of Perioperative Ketamine and Esketamine on Postoperative Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Kaunas). 2026;62(6). doi:10.3390/medicina62061156. PMID: 42356168.
- Yang X, Gao T, Wang S, Hu L, Huang F, Cui W, et al. Efficacy and safety of perioperative esketamine in improving postoperative sleep disturbances: A systematic review and meta-analysis. J Clin Anesth. 2026;113:112246. doi:10.1016/j.jclinane.2026.112246. PMID: 42259161.
- Zhao J, Yan Y, Wang X, Zhang C, Wang J. Effects of Esketamine on Postoperative Sleep Quality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nat Sci Sleep. 2026;18:575454. doi:10.2147/NSS.S575454. PMID: 42125425.
- Qiu D, Wang XM, Yang JJ, Chen S, Yue CB, Hashimoto K, et al. Effect of Intraoperative Esketamine Infusion on Postoperative Sleep Disturbance After Gynecological Laparoscopy: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(12):e2244514. doi:10.1001/jamanetworkopen.2022.44514. PMID: 36454569.
- Song Z, Miao M, Huang F, Hu L, Yang X, Cui W, et al. Effect of a single low-dose esketamine administration during surgical abortion on postoperative sleep disturbance: a randomized controlled trial. Nat Commun. 2025;16(1):7533. doi:10.1038/s41467-025-62933-1. PMID: 40804260.
- Ju LY, Liu GQ, Yuan L, Lyu L, Su Y, Liu AJ. Effect of Esketamine on Postoperative Delirium and Inflammatory Response in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting: A Randomized Controlled Study. J Cardiothorac Vasc Anesth. 2025;39(8):2079-2087. doi:10.1053/j.jvca.2025.04.013. PMID: 40320348.
- Huang C, Zhao X, Geng S, Sun S, Mousa NM, Xia H, et al. Non-drug perioperative interventions to reduce postoperative pulmonary complications after abdominal surgery: systematic review and meta-analysis. BMJ. 2026;393:e089001. doi:10.1136/bmj-2025-089001. PMID: 41956522.
- Xu X, Cheung DST, Smith R, Lai AYK, Lin CC. The effectiveness of pre- and post-operative rehabilitation for lung cancer: A systematic review and meta-analysis on postoperative pulmonary complications and length of hospital stay. Clin Rehabil. 2022;36(2):172-189. doi:10.1177/02692155211043267. PMID: 34496658.
- Pu CY, Batarseh H, Zafron ML, Mador MJ, Yendamuri S, Ray AD. Effects of Preoperative Breathing Exercise on Postoperative Outcomes for Patients With Lung Cancer Undergoing Curative Intent Lung Resection: A Meta-analysis. Arch Phys Med Rehabil. 2021;102(12):2416-2427.e4. doi:10.1016/j.apmr.2021.03.028. PMID: 33930327.
- Li D, Lv Y, Wang R, Li J, Zhang Y, Rong Y, et al. Effects of prehabilitation on outcomes among patients undergoing surgery for lung cancer: a systematic review and meta-analysis of randomized controlled trials. J Thorac Dis. 2026;18(6):656. doi:10.21037/jtd-2026-0694. PMID: 42444881.
- Chen QQ, Liang Y, Xu Y, Zhao LF. Preoperative exercise-based prehabilitation for reducing postoperative pulmonary complications after lung cancer surgery: a systematic review and meta-analysis. Front Med (Lausanne). 2026;13:1899789. doi:10.3389/fmed.2026.1899789. PMID: 42656529.
- Chen Y, Kang S, Li R, Cao Z, Leng J, Jin K, et al. Enhanced recovery after surgery programs versus conventional rehabilitation for patients undergoing thoracoscopic radical resection of lung cancer in local regional hospitals: a prospective randomized controlled trial. Surg Endosc. 2025;39(9):5811-5819. doi:10.1007/s00464-025-11877-0. PMID: 40696211.
- Han S, Wu X, Li P, He K, Li J. The impact of goal-directed fluid therapy on postoperative pulmonary complications in patients undergoing thoracic surgery: a systematic review and meta-analysis. J Cardiothorac Surg. 2024;19(1):60. doi:10.1186/s13019-024-02519-y. PMID: 38317166.
- Dolic D, Salvitti S. Efficacy of positive expiratory pressure in the prevention and treatment of postoperative pulmonary complications following thoracic and abdominal surgery. A systematic review and meta-analysis. Monaldi Arch Chest Dis. 2026;96(2). doi:10.4081/monaldi.2026.3735. PMID: 41645725.
- Kotta PA, Ali JM. Incentive Spirometry for Prevention of Postoperative Pulmonary Complications After Thoracic Surgery. Respir Care. 2021;66(2):327-333. doi:10.4187/respcare.07972. PMID: 32843511.
- Fu Y, Zhang YW, Gao J, Fu HM, Si L, Gao YT. Effects of lung-protective ventilation strategy on lung aeration loss and postoperative pulmonary complications in moderate-risk patients undergoing abdominal surgery. Minerva Anestesiol. 2021;87(6):655-662. doi:10.23736/S0375-9393.20.14951-4. PMID: 33325216.
- Zhu M, Song T, Bao Q, Wang J, Wang J, Wang W, et al. Effects of individualized PEEP titration on intraoperative cardiac output in thoracoscopic lung surgery: a prospective randomized trial. Sci Rep. 2026;16(1). doi:10.1038/s41598-026-43122-6. PMID: 41820516.
- Liu X, Zhao Z, Wu Q, Luo C, Xiao C, Luo T, et al. Effects of pressure versus volume controlled ventilation on postoperative pulmonary complications during elderly trendelenburg laparoscopic surgery. Sci Rep. 2026;16(1). doi:10.1038/s41598-026-55547-0. PMID: 42331924.
- Tian L, Wang Y, Bu Y, Wang Y, Che G. Effect of sugammadex on postoperative pulmonary complications in patients undergoing video-assisted thoracoscopic lung surgery. Front Oncol. 2026;16:1730277. doi:10.3389/fonc.2026.1730277. PMID: 41959913.
- Hung KC, Weng HL, Wu JY, Hsu CW, Yang CP, Lai YC, et al. Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Association with Postoperative Atelectasis After Video-Assisted Thoracoscopic Surgery: A Propensity Score-Matched Cohort Study. Drug Des Devel Ther. 2026;20:593657. doi:10.2147/DDDT.S593657. PMID: 41822908.
- Tan Y, Chen Z, Ji W, Li C, Zhang Y, Zhao Y, et al. Effect of non-intubated anesthesia video-assisted thoracoscopic surgery on postoperative diaphragm function and pulmonary complications in patients undergoing lung surgery: a randomized clinical trial. Int J Surg. 2026;112(2):3213-3222. doi:10.1097/JS9.0000000000003842. PMID: 41416613.
- Xu R, Yang L, Kong P, Yang W, Zhu Y, Xue Y, et al. Impact of nonintubated versus intubated anesthesia on postoperative pulmonary complications after video-assisted thoracoscopic lung resection: A retrospective cohort study. J Int Med Res. 2026;54(7):3000605261469830. doi:10.1177/03000605261469830. PMID: 42478082.
- Tian J, Xu M, Li S, Liu Y, Li W, Sun W, et al. Effects of low-dose esketamine on hypoxaemia during thoracoscopic non-tracheal intubation anaesthesia: protocol for a double-blind, randomised controlled trial. BMJ Open. 2026;16(1):e109633. doi:10.1136/bmjopen-2025-109633. PMID: 41592832.
- Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1-9. doi:10.1016/j.jncc.2022.02.002. PMID: 39035212.